Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. - Wikidata - awgldk - TriplyDB

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

http://www.wikidata.org/entity/Q34041792

about

Clinical manufacturing of CAR T cells: foundation of a promising therapy Role of the tumor microenvironment in mature B-cell lymphoid malignancies CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives Current challenges and novel treatment strategies in double hit lymphomas Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Novel immunotherapies in lymphoid malignancies Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Lymphoma Immunotherapy: Current Status Cellular immunotherapy as a beacon of hope for hematological malignancies CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma CAR T Cell Therapy: A Game Changer in Cancer Treatment Novel immunotherapies for hematologic malignancies Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Novel Drugs in Follicular Lymphoma Advances in Cancer Immunotherapy in Solid Tumors CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia T-cell receptor gene therapy--ready to go viral?CAR therapy: the CD19 paradigm CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies Smart CARs engineered for cancer immunotherapy Designing chimeric antigen receptors to effectively and safely target tumors Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Autologous lymphapheresis for the production of chimeric antigen receptor T cells.Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Immunotherapy in hematologic malignancies: past, present, and future.Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells Genome-Edited T Cell Therapies.Engineering cord blood to improve engraftment after cord blood transplant.A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Biology and clinical application of CAR T cells for B cell malignancies

P2860

Q26747037-ADC3E25C-759E-407B-8750-C87466C787CD Q26748775-791218B8-C585-48CF-9B6A-EC7956718D10 Q26749139-84235283-8AE7-4DAB-B2FA-3290C38CC2FF Q26753082-C5422382-3B7A-4422-8776-575F36E66D85 Q26769595-774C771B-6365-45DB-819C-F984139EBEE7 Q26770385-44A63440-5F97-4762-9FAC-EC030F88EA31 Q26773309-E0E3D4E4-21D6-4298-A4C4-203827CE3290 Q26775720-71EDC992-9148-464A-8BB2-3BB4437A9F36 Q26777394-67707613-3B78-45AF-B313-33B748444CF6 Q26777403-7160621B-7D85-4F6A-9320-12B8A09320E7 Q26778759-E29A23C8-D814-434A-BDE4-19E123F64A26 Q26782902-B84EF84E-49A4-4099-B3D6-B447D2F6B3AC Q26784288-8E363399-0667-4C34-AD50-EC810A9A6156 Q26800814-338C95F0-E948-4400-AFEA-8FAAD5E60247 Q26822769-3FC1E7B4-8750-45E4-8FD8-F16B1069D99E Q27004436-68EE1530-AC45-499D-B7AE-68D4F85E9DCF Q27011297-AE437304-17CC-46BC-AA8C-C6BC27A42CFE Q27304386-E50BC1FE-6B92-415F-BC59-9D0D50430FC4 Q28076335-9C813804-34D9-4E3A-8671-6879C5E35833 Q28080113-1E13973E-7459-4087-9599-8A0A3C2729AF Q28081600-DF36E06C-448D-400C-929B-E5A07F9347C9 Q28081611-6365AB90-9C4B-4B81-9630-F7AF67157447 Q28081642-E277444E-ABB7-40CF-8526-21971B07F265 Q28083296-3657AA25-AA03-48D3-9C86-A4ACFC2E8F6E Q28085769-B37EDA61-71D4-4FE8-9BF4-90B8DFA7DA9B Q28087236-023AF638-7BFB-44BD-BC5C-F8C1257F1F8E Q28088526-E8F40A47-0D11-46D9-80FA-9C446B959D25 Q28276800-219B4329-D4EE-41F8-8BFF-1F27A9FF18D9 Q30248407-3243016F-618F-4664-815A-D7FB7795064A Q30253090-AABDA2C7-A5DF-45AF-AE2C-A53700896EEC Q30399332-76D232F9-325D-4B41-B307-DA1ABB06116A Q30764873-D4D98D94-ACBF-4BA2-91B3-406F29583A73 Q33593865-D948E25A-E8BE-4F31-B18D-A965AF896E3F Q33686036-3EEF070A-E2CD-4C62-9563-F5847CC1A56A Q33729598-45ADC62D-BFF2-4DBC-AF06-20A25264FD9D Q33766995-FA6D63C0-9177-40F9-9680-D2DF60725F75 Q33803754-81B7C550-3F73-45AF-8B6F-29FD8FD16F39 Q33823270-F81FE85A-4CEC-431F-9893-8D1A0D634BE6 Q33851168-0EC9D040-F234-4513-918C-DD00A4AA9C91 Q33907565-250C0133-A312-4EF9-9AC6-1EA5F93C9DC2

P2860

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

http://www.wikidata.org/entity/Q34041792

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@ast

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@en

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@nl

type

label

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@ast

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@en

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@nl

prefLabel

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@ast

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@en

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@nl

P1433

Q34041792-BA2F7C56-0B22-4BBD-96D0-24E842BD51AD

P1476

Q34041792-0213D9CC-4B8F-4602-A392-EBB076A537BD

P2093

Q34041792-1388AF94-6153-462C-BB7B-C910CADD4856

Q34041792-14073237-A77B-4E0A-BA0A-F1C53BD21340

Q34041792-1B968C3C-C37D-41A2-BABB-62D79EA487C9

Q34041792-22AB2843-7D7F-450F-8A05-A909A81C5EAB

Q34041792-2E63310C-3F16-4512-9C71-08FF131432EE

Q34041792-359AF699-FE90-4605-B434-2817EDBBAA4E

Q34041792-361B33AB-F8C5-4EFF-810F-03C05E24CBE0

Q34041792-3874EC09-AC2B-40FC-BE4B-9A5800688CBE

Q34041792-3A8EA282-79E2-4850-8E6F-3388668570C8

Q34041792-4CA3B0CC-2C96-409C-91E9-747ABAD755B8

P2860

Q34041792-0A6AC03E-FEB5-436A-8162-4834D59CDFC3

Q34041792-0CAD772D-5789-460A-BE47-7A75EA59AADA

Q34041792-15D6D339-3F30-4AE1-B200-F567165DB626

Q34041792-240016D7-1BF0-44C2-AE33-DF4B07799AFC

Q34041792-274D42A6-2F2C-4137-95D3-A957632A48CF

Q34041792-2F6A03FB-D405-44F8-9C62-3B14BBA24538

Q34041792-31333AD7-350C-4213-A4AB-BAF8548C916B

Q34041792-33797F83-D579-40C6-A704-0428E12597AA

Q34041792-3422C522-A2AA-4D30-A50A-A04E60B9371C

Q34041792-36197324-D8A8-406A-A5FA-CC2532B09D6E

P304

Q34041792-6512967E-7C1D-4D19-8288-00459F2435F9

P31

Q34041792-B733884C-D3BF-40E7-83D1-C9906A2CDA1B

P356

Q34041792-EAF8DA86-946B-4B5D-B1FB-795A5C2C333D

P407

Q34041792-87710FBF-8953-4177-AF28-70F72A8F5457

P433

Q34041792-17595716-4CAE-4D5D-A0B9-A0102F11EF40

P478

Q34041792-8358873A-645D-422E-8AF4-91EF48C9B442

P577

Q34041792-8E454BA4-51B4-46FD-AD41-6A96D51FE0B7

P698

Q34041792-7F9A9878-0043-44E9-BF54-D31A2592A2C4

P921

Q34041792-3E79AE1C-FB23-4684-8567-EF456E1C7CF6

P932

Q34041792-4D78BEB2-B143-44D5-B499-EC74B45CC682

P356

JCO.2014.56.2025

P1433

Journal of Clinical Oncology

P1476

Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.

@en

P2093

Andre Goy

http://www.w3.org/2001/XMLSchema#string

Avindra Nath

http://www.w3.org/2001/XMLSchema#string

Clara C Chen

http://www.w3.org/2001/XMLSchema#string

David E Spaner

http://www.w3.org/2001/XMLSchema#string

Debbie-Ann N Nathan

http://www.w3.org/2001/XMLSchema#string

Giao Q Phan

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

James N Kochenderfer

http://www.w3.org/2001/XMLSchema#string

Kathleen E Morton

http://www.w3.org/2001/XMLSchema#string

Lien T Ngo

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

Central memory and effector memory T cell subsets: function, generation, and maintenance

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

P304

540-549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.56.2025

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25154820

http://www.w3.org/2001/XMLSchema#string

P921

P932

4322257

http://www.w3.org/2001/XMLSchema#string